Drug intelligence / Profile preview

etofenamate

Development stage
Phase 4
Lead developer
Bayer
Modality
Small Molecules
Administration
Topical, Intramuscular
01

Overview

Etofenamate is a nonsteroidal anti-inflammatory drug (NSAID) of the flufenamic acid derivative group used primarily for the topical treatment of joint and muscular pain. It is available as a cream, gel, or spray for local application and can also be administered intramuscularly in some settings. Etofenamate exerts its effects by inhibiting both cyclooxygenase (COX) and lipoxygenase enzymes, thereby reducing prostaglandin and leukotriene synthesis. This dual inhibition results in analgesic and anti-inflammatory properties. Additionally, etofenamate inhibits other inflammatory mediators such as histamine release, bradykinin antagonism, serotonin antagonism, complement system activity inhibition, and hyaluronidase inhibition[5][6][7]. It is indicated for localized painful conditions of the musculoskeletal system including arthropathies (joint diseases), myalgias (muscle pain), bursitis (inflammation of fluid-filled sacs around joints), neuralgia (nerve pain), contusions (bruises), strains or sprains[5]. Due to poor oral bioavailability it is not administered orally[6].

Brand names
RheumonTraumonFlexagil
Other names
etofenamate
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)Bradykinin B2 receptorComplement (Complement system)HYAL (Hyaluronidase family (HYAL))15-LOX (Lysyl Oxidase)5-HT (Serotonin receptors)

Beyond the preview

Go deeper on etofenamate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on etofenamate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call